Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: A systematic review and meta-analysis

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 8, 2010, Pages 1551-1561

  Chang, Kwok Chiu ^a   Yew, Wing Wai ^b   Yeung Chan, Raphael Chiu ^c  

^a DEPARTMENT OF HEALTH   (China)

^b GRANTHAM HOSPITAL   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Drug susceptibility testing; Fluoroquinolones; Molecular; Resistant; Tuberculosis

Indexed keywords

LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; BACTERIAL DNA; BACTERIAL PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; DNA SEQUENCE; DRUG DETERMINATION; DRUG SENSITIVITY; GENE TARGETING; GENOTYPE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; DRUG EFFECTS; EVALUATION STUDY; GENETICS; HUMAN; ISOLATION AND PURIFICATION; META ANALYSIS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PROCEDURES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; AZA COMPOUNDS; BACTERIAL PROTEINS; DNA GYRASE; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; GENOTYPE; HUMANS; LEVOFLOXACIN; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; QUINOLINES; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 77954717318     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq202     Document Type: Article

References (60)

1. WHO. Anti-Tuberculosis Drug Resistance in the World: Fourth Global Report. WHO/HTM/TB/2008.394. Geneva: WHO, 2008.
2. Chan ED, Laurel V, Strand MJ et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169: 1103-9.
3. Leimane V, Riekstina V, Holtz TH et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365: 318-26.
4. Yew WW, Chan CK, Chau CH et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000; 117: 744-51.
5. Migliori GB, Lange C, Girardi E et al. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Eur Respir J 2008; 31: 904-5.
6. Migliori GB, Besozzi G, Girardi E et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 2007; 30: 623-6.
7. Van Deun A, Martin A, Palomino JC. Diagnosis of drug-resistant tuberculosis: reliability and rapidity of detection. Int J Tuberc Lung Dis 2010; 14: 131-40.
8. Palomino JC. Newer diagnostics for tuberculosis and multi-drug resistant tuberculosis. Curr Opin Pulm Med 2006; 12: 172-8.
9. Barnard M, Albert H, Coetzee G et al. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 2008; 177: 787-92.
10. Antonova OV, Gryadunov DA, Lapa SA et al. Detection of mutations in Mycobacterium tuberculosis genome determining resistance to fluoroquinolones by hybridization on biological microchips. Bull Exp Biol Med 2008; 145: 108-13.
11. Hillemann D, Rusch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2009; 47: 1767-72.
12. Martin A, Palomino JC, Portaels F. Rapid detection of ofloxacin resistance in Mycobacterium tuberculosis by two low-cost colorimetric methods: resazurin and nitrate reductase assays. J Clin Microbiol2005; 43:1612-6.
13. Devasia RA, Blackman A, May C et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance. J Antimicrob Chemother 2009; 63: 1173-8.
14. Sekiguchi J, Miyoshi-Akiyama T, Augustynowicz-Kopec E et al. Detection of multidrug resistance in Mycobacterium tuberculosis. J Clin Microbiol 2007; 45: 179-92.
15. El-Sayed Zaki M, Goda T. Rapid phenotypic assay of antimycobacterial susceptibility pattern by direct mycobacteria growth indicator tube and phage amplified biological assay compared to BACTEC 460 TB. Tuberculosis (Edinb) 2007; 87: 102-8.
16. Ejigu GS, Woldeamanuel Y, Shah NS et al. Microscopic-observation drug susceptibility assay provides rapid and reliable identification of MDR-TB. Int J Tuberc Lung Dis 2008; 12: 332-7.
17. Irwig L, Macaskill P, Glasziou P et al. Meta-analytic methods for diagnostic test accuracy. J Clin Epidemiol 1995; 48: 119-30. discussion 131-2.
18. Lijmer JG, Bossuyt PMM, Heisterkamp SH. Exploring sources of heterogeneity in systematic reviews of diagnostic tests. Stat Med 2002; 21: 1525-37.
19. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 1993; 12: 1293-316.
20. Reitsma JB, Glas AS, Rutjes AWS et al. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005; 58: 982-90.
21. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000; 53: 1119-29.
22. Zamora J, Abraira V, Muriel A et al. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006; 6: 31.
23. Bravo LTC, Tuohy MJ, Ang C et al. Pyrosequencing for rapid detection of Mycobacterium tuberculosis resistance to rifampin, isoniazid, and fluoroquinolones. J Clin Microbiol 2009; 47: 3985-90.
24. Chan RCY, Hui M, Chan EWC et al. Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong. J Antimicrob Chemother 2007; 59: 866-73.
25. Cheng AFB, Yew WW, Chan EWC et al. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 2004; 48: 596-601.
26. Feuerriegel S, Cox HS, Zarkua N et al. Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment. Antimicrob Agents Chemother 2009; 53: 3353-6.
27. Giannoni F, Iona E, Sementilli F et al. Evaluation of a new line probe assay for rapid identification of gyrA mutations in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005; 49: 2928-33.
28. Kam KM, Yip CW, Cheung TL et al. Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility. Microb Drug Resist 2006; 12: 7-11.
29. Kruuner A, Yates MD, Drobniewski FA. Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J Clin Microbiol 2006; 44: 811-8.
30. Martin A, von Groll A, Fissette K et al. Rapid detection of Mycobacterium tuberculosis resistance to second-line drugs by use of the manual mycobacterium growth indicator tube system. J Clin Microbiol 2008; 46: 3952-6.
31. Martin A, Paasch F, Von Groll A et al. Thin-layer agar for detection of resistance to rifampicin, ofloxacin and kanamycin in Mycobacterium tuberculosis isolates. Int J Tuberc Lung Dis 2009; 13: 1301-4.
32. Martin A, Camacho M, Portaels F et al. Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: rapid, simple, and inexpensive method. Antimicrob Agents Chemother 2003; 47: 3616-9.
33. Rodrigues C, Jani J, Shenai S et al. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System. Int J Tuberc Lung Dis 2008; 12: 1449-55.
34. Rosales S, Pineda-Garcia L, Andino N et al. Evaluation of the nitrate reductase assay for rapid detection of extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis 2009; 13: 1542-9.
35. Rusch-Gerdes S, Pfyffer GE, Casal M et al. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 2006; 44: 688-92.
36. Shi R, Zhang J, Li C et al. Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing. J Clin Microbiol 2006; 44: 4566-8.
37. Sougakoff W, Lemaitre N, Cambau E et al. Nonradioactive single-strand conformation polymorphism analysis for detection of fluoroquinolone resistance in mycobacteria. Eur J Clin Microbiol Infect Dis 1997; 16:395-8.
38. Umubyeyi AN, Martin A, Zissis G et al. Evaluation of the resazurin microtiter assay for rapid detection of ofloxacin resistance in M. tuberculosis. Int J Tuberc Lung Dis 2006; 10: 808-11.
39. Von Groll A, Martin A, Jureen P et al. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob Agents Chemother 2009; 53: 4498-500.
40. Xu P, Li X, Zhao M et al. Prevalence of fluoroquinolone resistance among tuberculosis patients in Shanghai, China. Antimicrob Agents Chemother 2009; 53: 3170-2.
41. van Doorn HR, An DD, de Jong MD et al. Fluoroquinolone resistance detection in Mycobacterium tuberculosis with locked nucleic acid probe real-time PCR. Int J Tuberc Lung Dis 2008; 12: 736-42.
42. Shi R, Otomo K, Yamada H et al. Temperature-mediated heteroduplex analysis for the detection of drug-resistant gene mutations in clinical isolates of Mycobacterium tuberculosis by denaturing HPLC, SURVEYOR nuclease. Microbes Infect 2006; 8: 128-35.
43. Lin SG, Desmond E, Bonato D et al. Multicenter evaluation of Bactec MGIT 960 system for second-line drug susceptibility testing of Mycobacterium tuberculosis complex. J Clin Microbiol 2009; 47: 3630-4.
44. Sanders CA, Nieda RR, Desmond EP. Validation of the use of Middlebrook 7H10 agar, BACTEC MGIT 960, and BACTEC 460 12B media for testing the susceptibility of Mycobacterium tuberculosis to levofloxacin. J Clin Microbiol 2004; 42: 5225-8.
45. Hui M, Chan EWC, Chin ML et al. Genotypic rpoB and gyrA profiles for detection of rifampicin and fluoroquinolone susceptibilities of Mycobacterium tuberculosis isolates directly from clinical sputum specimens. Int J Antimicrob Agents 2009; 34: 186-7.
46. Sulochana S, Narayanan S, Paramasivan CN et al. Analysis of fluoroquinolone resistance in clinical isolates of Mycobacterium tuberculosis from India. J Chemother 2007; 19: 166-71.
47. Devasia RA, Blackman A, Gebretsadik Tet al. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med 2009; 180:365-70.
48. Huang T, Kunin CM, Shin-Jung Lee S et al. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. J Antimicrob Chemother 2005; 56: 1058-62.
49. Tuberculosis and Chest Service of the Department of Health. Annual Report 2006. The Government of Hong Kong Special Administrative Region. http://www.info.gov.hk/tb_chest/contents/c56.htm (7 March 2010, date last accessed).
50. WHO. Treatment of Tuberculosis: Guidelines-Fourth Edition. WHO/HTM/TB/2009.420. Geneva: WHO, 2010.
51. Alangaden GJ, Manavathu EK, Vakulenko SB et al. Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients. Antimicrob Agents Chemother 1995; 39: 1700-3.
52. Lee ASG, Tang LLH, Lim IHK et al. Characterization of pyrazinamide and ofloxacin resistance among drug resistant Mycobacterium tuberculosis isolates from Singapore. Int J Infect Dis 2002; 6: 48-51.
53. Pitaksajjakul P, Wongwit W, Punprasit W et al. Mutations in the gyrA and gyrB genes of fluoroquinolone-resistant Mycobacterium tuberculosis from TB patients in Thailand. Southeast Asian J Trop Med Public Health 2005; 36 Suppl 4: 228-37.
54. Takiff HE, Salazar L, Guerrero C et al. Cloningandnucleotidesequenceof Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 1994; 38: 773-80.
55. Wang J, Lee L, Lai H et al. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother 2007; 59: 860-5.
56. Drlica K, Malik M. Fluoroquinolones: action and resistance. Curr Top Med Chem 2003; 3: 249-82.
57. Sreevatsan S, Pan X, Stockbauer KE et al. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proc Natl Acad Sci USA 1997; 94: 9869-74.
58. Walter SD. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med 2002; 21: 1237-56.
59. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
60. Angeby KA, Klintz L, Hoffner SE et al. Rapid and inexpensive drug susceptibility testing of Mycobacterium tuberculosis with a nitrate reductase assay. J Clin Microbiol 2002; 40: 553-5.